Homotypic and Heterotypic Protection and Risk of Reinfection Following Natural Norovirus Infection in a Highly Endemic Setting.
GII.4
heterotypic protection
homotypic protection
norovirus
reinfection
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
27 01 2021
27 01 2021
Historique:
received:
08
07
2019
accepted:
08
01
2020
entrez:
27
1
2021
pubmed:
28
1
2021
medline:
29
4
2021
Statut:
ppublish
Résumé
Norovirus is a leading cause of acute gastroenteritis worldwide, yet there is limited information on homotypic or heterotypic protection following natural infection to guide vaccine development. A total of 6020 stools collected from 299 Peruvian children between 2010 and 2014 were tested by norovirus real-time reverse-transcription polymerase chain reaction followed by sequence-based genotyping. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) of infection among children with vs without prior exposure. Norovirus was detected in 1288 (21.3%) samples. GII.4 (26%), GII.6 (19%), and GI.3 (9%) viruses accounted for 54% of infections. Homotypic protection for GI.3 (HR, 0.35; P = .015), GI.7 (HR, 0.19; P = .022), GII.4 (HR, 0.39; P < .001), and GII.6 (HR, 0.52; P = .006) infections was observed. Hazard analysis showed that children with prior GII.4 infection exhibited heterotypic protection with a 48% reduction of subsequent GI.3 infection (HR, 0.52; P = .005). Prior exposure to GI.3, GII.2, and GII.17 infections enhanced susceptibility to subsequent infections with several other norovirus genotypes. Children up to 2 years of age infected with GII.4 noroviruses demonstrated both homotypic and heterotypic protection to reinfection with other genotypes. These data support the need for ongoing vaccine development efforts with GII.4 as the main component and caution the inclusion of genotypes that may enhance susceptibility to infections.
Sections du résumé
BACKGROUND
Norovirus is a leading cause of acute gastroenteritis worldwide, yet there is limited information on homotypic or heterotypic protection following natural infection to guide vaccine development.
METHODS
A total of 6020 stools collected from 299 Peruvian children between 2010 and 2014 were tested by norovirus real-time reverse-transcription polymerase chain reaction followed by sequence-based genotyping. Cox proportional hazards models were used to derive adjusted hazard ratios (HRs) of infection among children with vs without prior exposure.
RESULTS
Norovirus was detected in 1288 (21.3%) samples. GII.4 (26%), GII.6 (19%), and GI.3 (9%) viruses accounted for 54% of infections. Homotypic protection for GI.3 (HR, 0.35; P = .015), GI.7 (HR, 0.19; P = .022), GII.4 (HR, 0.39; P < .001), and GII.6 (HR, 0.52; P = .006) infections was observed. Hazard analysis showed that children with prior GII.4 infection exhibited heterotypic protection with a 48% reduction of subsequent GI.3 infection (HR, 0.52; P = .005). Prior exposure to GI.3, GII.2, and GII.17 infections enhanced susceptibility to subsequent infections with several other norovirus genotypes.
CONCLUSIONS
Children up to 2 years of age infected with GII.4 noroviruses demonstrated both homotypic and heterotypic protection to reinfection with other genotypes. These data support the need for ongoing vaccine development efforts with GII.4 as the main component and caution the inclusion of genotypes that may enhance susceptibility to infections.
Identifiants
pubmed: 33501947
pii: 5699601
doi: 10.1093/cid/ciaa019
pmc: PMC7840104
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
222-229Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Pediatr Infect Dis J. 2007 Jan;26(1):46-9
pubmed: 17195705
J Clin Virol. 2011 Jun;51(2):121-5
pubmed: 21514213
Pediatr Infect Dis J. 2009 Oct;28(10):879-84
pubmed: 19672213
J Infect Dis. 2018 Nov 5;218(12):1937-1942
pubmed: 30053045
Clin Infect Dis. 2016 May 15;62(10):1210-7
pubmed: 27013692
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S193-206
pubmed: 25305287
J Virol. 2013 Jun;87(11):6270-82
pubmed: 23536665
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S225-32
pubmed: 25305291
Epidemiol Infect. 2013 Aug;141(8):1572-84
pubmed: 23507473
J Clin Microbiol. 2017 Jul;55(7):2208-2221
pubmed: 28490488
PLoS Med. 2015 Mar 24;12(3):e1001807
pubmed: 25803642
J Infect Dis. 2015 Mar 15;211(6):879-88
pubmed: 25210139
Pediatr Infect Dis J. 2009 Sep;28(9):844-7
pubmed: 19636281
J Infect Dis. 1974 Jun;129(6):709-14
pubmed: 4209723
Clin Infect Dis. 2014 Nov 1;59 Suppl 4:S310-6
pubmed: 25305303
J Virol. 2018 Jul 31;92(16):
pubmed: 29848591
J Gen Virol. 2019 Oct;100(10):1393-1406
pubmed: 31483239
Pediatr Infect Dis J. 2014 Nov;33(11):1156-63
pubmed: 24879131
J Pediatric Infect Dis Soc. 2019 Nov 6;8(5):414-421
pubmed: 30184153
J Med Virol. 2019 May;91(5):738-743
pubmed: 30570784
J Infect Dis. 2015 Jun 1;211(11):1813-21
pubmed: 25505295
Clin Infect Dis. 2014 Feb;58(4):483-91
pubmed: 24300042
PLoS One. 2015 Dec 03;10(12):e0142927
pubmed: 26632843
J Clin Virol. 2008 Nov;43(3):346-8
pubmed: 18789755
Stat Med. 1989 Aug;8(8):977-85
pubmed: 2799126
Clin Infect Dis. 2019 Jul 2;69(2):357-365
pubmed: 30753367
Epidemiol Infect. 2015 Jun;143(8):1710-7
pubmed: 25336060
Viruses. 2019 Apr 10;11(4):
pubmed: 30974898
N Engl J Med. 2009 Oct 29;361(18):1776-85
pubmed: 19864676
Lancet Infect Dis. 2014 Aug;14(8):725-730
pubmed: 24981041
Biometrics. 1979 Mar;35(1):25-39
pubmed: 497336
Genome Announc. 2018 Feb 8;6(6):
pubmed: 29439030
PLoS One. 2016 Apr 26;11(4):e0146972
pubmed: 27115152
PLoS Pathog. 2017 Jan 19;13(1):e1006136
pubmed: 28103318